A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- AstraZeneca
- Study ID
- NCT06173570
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- AZD0780 — DRUGAZD0780 administered orally, once daily for 12 weeks
- Placebo — DRUGPlacebo administered orally, once daily for 12 weeks
Study Details
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.
Key Dates
- Start date
- Jan 19, 2024
- Status verified
- Nov 2025
- Primary completion
- Sep 30, 2024
- Completion
- Sep 30, 2024
Study Design
- Enrollment
- 428 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm AAZD0780, Dose 1
- Experimental: Arm BAZD0780, Dose 2
- Experimental: Arm CAZD0780, Dose 3
- Experimental: Arm DAZD0780, Dose 4
- Placebo Comparator: Arm EPlacebo, matched for appearance
Primary Outcome Measure
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 [ Time Frame: From first day of treatment up to week 12 ]
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Huntsville | Alabama | 35801 | - |
| Research Site | Lincoln | California | 95648 | - |
| Research Site | Palm Springs | California | 92262 | - |
| Research Site | Santa Ana | California | 92704 | - |
| Research Site | Boca Raton | Florida | 33434 | - |
| Research Site | Hialeah | Florida | 33012 | - |
| Research Site | Inverness | Florida | 34452 | - |
| Research Site | Jacksonville | Florida | 32216 | - |
| Research Site | Indianapolis | Indiana | 46260 | - |
| Research Site | Louisville | Kentucky | 40213 | - |
| Research Site | New Windsor | New York | 12553 | - |
| Research Site | Greensboro | North Carolina | 27408 | - |
| Research Site | Fargo | North Dakota | 58104 | - |
| Research Site | San Marcos | Texas | 78666 | - |
Find similar trials in Huntsville, AL
Related Studies
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With DyslipidemiaPHASE1 · Recruiting · AstraZeneca · Glendale, California
- Patient-engaged Development and Testing of Educational Content on Side Effects of StatinsEnrolling By Invitation · Weill Medical College of Cornell University · New York, New York
- Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot TrialRecruiting · Indiana University · Indianapolis, Indiana
- Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins DietPHASE1/PHASE2 · Enrolling By Invitation · Johns Hopkins University · Baltimore, Maryland